Patient Characteristics (n = 8)
| SUVmax | SUVmax 18F-FLT | |||||||||||
| Patient no. | Age (y) | Sex | Stage (Ann Arbor) | Histology (14) | Treatment | Ki67 (%) | MIPI score | MIPI-Ki67score | 18F-FDG | 18F-FLT | Mean ± SD | Range |
| 1 | 87 | Male | IVAE | Classic | R | 35 | 6.6 (high) | 7.3 (high) | NA | NA | NA | |
| 2 | 71 | Male | IVAE | Classic | R-Benda | 10 | 6.1 (intermediate) | 6.3 (intermediate) | 4.0 | 6.2 | 3.9 ± 2.1 | 2.0–6.2 |
| 3 | 80 | Female | IIA | Classic | R-Benda | 5 | 7.1 (high) | 7.2 (high) | 10.7 | 8.6 | 8.2 ± 0.7 | 7.7–8.6 |
| 4 | 65 | Male | IVBE | Classic | MCL-2 | 10 | 6.0 (intermediate) | 6.2 (intermediate) | 5.6 | 7.7 | 5.8 ± 1.2 | 4.5–7.7 |
| 5 | 75 | Female | IVB | Blastoid | R-Benda | 85 | 6.2 (intermediate) | 8.0 (high) | 11.7 | 19.6 | 17.6 ± 2.6 | 14.5–19.6 |
| 6 | 74 | Female | IVBE | Classic | R-CHOP | 40 | 7.1 (high) | 7.9 (high) | 9.6 | 15.1 | 11.4 ± 2.2 | 9.3–15.1 |
| 7 | 47 | Male | IVA | Blastoid | MCL-2 | 80 | 5.4 (low) | 7.1 (high) | 11.5 | 14.5 | 12.2 ± 2.9 | 8.2–14.5 |
| 8 | 67 | Male | IVA | Classic | R-CHOP | 1 | 6.3 (intermediate) | 6.4 (intermediate) | 8.5 | 9.5 | 7.6 ± 1.3 | 6.3–9.5 |
R = rituximab; NA = not applicable in patient with no uptake; R-Benda = rituximab, bendamustin; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; MCL-2 (analog) = rituximab-maxiCHOP, alternating with rituximab high-dose cytarabin (3).